CA2461363A1 - Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors - Google Patents

Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors Download PDF

Info

Publication number
CA2461363A1
CA2461363A1 CA002461363A CA2461363A CA2461363A1 CA 2461363 A1 CA2461363 A1 CA 2461363A1 CA 002461363 A CA002461363 A CA 002461363A CA 2461363 A CA2461363 A CA 2461363A CA 2461363 A1 CA2461363 A1 CA 2461363A1
Authority
CA
Canada
Prior art keywords
pyridyl
indole
alkyl
bromo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002461363A
Other languages
English (en)
French (fr)
Inventor
Gaetan H. Ladouceur
Michael J. Burke
Wai C. Wong
Donald Bierer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2461363A1 publication Critical patent/CA2461363A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002461363A 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors Abandoned CA2461363A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32499301P 2001-09-26 2001-09-26
US60/324,993 2001-09-26
PCT/US2002/030482 WO2003027094A2 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors

Publications (1)

Publication Number Publication Date
CA2461363A1 true CA2461363A1 (en) 2003-04-03

Family

ID=23265979

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002461363A Abandoned CA2461363A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
CA002461360A Abandoned CA2461360A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002461360A Abandoned CA2461360A1 (en) 2001-09-26 2002-09-26 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors

Country Status (5)

Country Link
EP (2) EP1432706A2 (https=)
JP (2) JP2005532983A (https=)
AU (2) AU2002340010A1 (https=)
CA (2) CA2461363A1 (https=)
WO (8) WO2003027085A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
CN101675928A (zh) * 2003-11-14 2010-03-24 沃泰克斯药物股份有限公司 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
WO2005099711A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
JP4602686B2 (ja) * 2004-04-15 2010-12-22 広栄化学工業株式会社 ２，６−ジハロゲノ−４−アリールピリジン類の製造法
EP1799659A1 (en) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
MX2007004781A (es) * 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
WO2006051723A1 (ja) * 2004-11-09 2006-05-18 Kaneka Corporation １－ハロ－３－アリール－２－プロパノン類の製造法
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
BRPI0519774A2 (pt) * 2005-01-19 2009-02-10 Biolipox Ab composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
KR20080066938A (ko) * 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
CA2635541A1 (en) * 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
BRPI0710479A2 (pt) * 2006-01-18 2012-08-14 Hoffmann La Roche composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.
BRPI0706411A2 (pt) * 2006-01-24 2011-03-29 Lilly Co Eli composto, composição farmacêutica, método de preparação de um indol ou um sal farmaceuticamente aceitável do mesmo, e, uso de um composto
EP2468727A1 (en) 2006-03-29 2012-06-27 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as MGLUR2 antagonists
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
ATE534642T1 (de) * 2006-09-21 2011-12-15 Eisai R&D Man Co Ltd Durch einen heteroarylring substituiertes pyridinderivat und antipilzmittel, das dieses enthält
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
RU2009116632A (ru) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
WO2008070350A2 (en) 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US8183263B2 (en) 2007-05-22 2012-05-22 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles
TWI580356B (zh) 2007-08-13 2017-05-01 孟山都科技有限責任公司 控制植物寄生性線蟲的化合物及方法以及被覆有該化合物之種子
JP5567481B2 (ja) 2007-10-09 2014-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとして有用なピリジン誘導体
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
CN101965176B (zh) 2008-02-08 2012-06-20 株式会社资生堂 美白剂和皮肤外用剂
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
AU2009330686B2 (en) * 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
TWI409265B (zh) * 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
KR20110128942A (ko) * 2009-03-19 2011-11-30 사노피 Ｈｓｐ９０ 억제 인다졸 유도체, 그를 함유하는 조성물 및 그의 용도
JP5728487B2 (ja) * 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式ヘテロ環化合物
WO2011051198A2 (de) * 2009-10-30 2011-05-05 Bayer Cropscience Ag Pyridin-derivate als pflanzenschutzmittel
DE102009058280A1 (de) 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
CN103140490A (zh) 2010-07-15 2013-06-05 百时美施贵宝公司 氮杂吲唑化合物
KR101823275B1 (ko) 2010-08-04 2018-03-08 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
MX2013001660A (es) 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
WO2012052412A1 (de) * 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
GB2485404A (en) * 2010-11-15 2012-05-16 Nat Univ Ireland Metal-complexed pyridyl-substituted tetrazole compounds and their use in treating cancer
CN102675286B (zh) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 一类吲唑类化合物及其制备方法、用途和药物组合物
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
US20120302573A1 (en) * 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
US8969586B2 (en) 2011-09-27 2015-03-03 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
EP2903615B1 (en) * 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
EP2934144B1 (en) 2012-12-20 2017-07-19 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
EP2968219B1 (en) 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
EP3191087A1 (en) 2014-09-12 2017-07-19 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
JP7193071B2 (ja) * 2017-02-08 2022-12-20 国立大学法人東海国立大学機構 蛍光発光材料および紫外線吸収剤
WO2021126779A1 (en) * 2019-12-18 2021-06-24 The Regents Of The University Of California Inhibitors of lin28 and methods of use thereof
US20210246109A1 (en) * 2020-02-11 2021-08-12 University Of Kentucky Research Foundation Potent and selective inhibitors of cytochrome p450
WO2023049199A1 (en) * 2021-09-24 2023-03-30 Zeno Management, Inc. Azole compounds
CN117551029A (zh) * 2023-11-22 2024-02-13 河南大学 一种4-溴-3-氰基吡啶的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150068C (da) * 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
DE3940476A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
JPH04154773A (ja) * 1990-10-15 1992-05-27 Green Cross Corp:The チアゾール誘導体
DE4117560A1 (de) * 1991-05-29 1992-12-03 Bayer Ag Verwendung von pyridinylpyrimidin-derivaten zum schutz technischer materialien
TW223004B (https=) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5599774A (en) * 1992-01-22 1997-02-04 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU217661B (hu) * 1992-03-09 2000-03-28 Zeneca Ltd. Aril-indazol-származékok, eljárás az előállításukra és herbicidként történő alkalmazásuk
AU689972B2 (en) * 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
US6046136A (en) * 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
EP1019399A1 (en) * 1997-10-03 2000-07-19 Merck Frosst Canada & Co. Aryl thiophene derivatives as pde iv inhibitors
CA2331118A1 (en) * 1998-05-12 1999-11-18 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
AU5227999A (en) * 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
AU2001237401B2 (en) * 2000-03-01 2006-11-09 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives

Also Published As

Publication number Publication date
AU2002340010A1 (en) 2003-04-07
WO2003027100A1 (en) 2003-04-03
WO2003027085A2 (en) 2003-04-03
WO2003027094A2 (en) 2003-04-03
WO2003027095A1 (en) 2003-04-03
WO2003027105A1 (en) 2003-04-03
CA2461360A1 (en) 2003-04-03
AU2002362603A1 (en) 2003-04-07
WO2003027085A3 (en) 2003-12-04
JP2005528325A (ja) 2005-09-22
JP2005532983A (ja) 2005-11-04
WO2003027094A3 (en) 2003-10-23
WO2003027096A1 (en) 2003-04-03
EP1432698A2 (en) 2004-06-30
WO2003027101A1 (en) 2003-04-03
EP1432706A2 (en) 2004-06-30
WO2003027107A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
CA2461363A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040236110A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040198773A1 (en) Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
JP6602470B2 (ja) Ｍｄｍ２−ｐ５３阻害薬としてのスピロ［３ｈ−インドール−３，２‘−ピロリジン］−２（１ｈ）−オン化合物及び誘導体
JP6488367B2 (ja) ベンゾイミダゾール誘導体
EP4598922B1 (en) Parg inhibitory compound
BR112015023279B1 (pt) compostos para inibição de fasn
BRPI0619517A2 (pt) ácidos pirazolo[1,5-a]piridina-3-carboxìlicos como inibidores de ephb e vegfr2 cinase
JP2011510058A (ja) Ｃ−ｍｅｔの阻害剤として活性な縮合ピリジン
EP2598481A1 (en) Sulfonamide compounds useful as cyp17 inhibitors
US9266880B2 (en) Substituted azaindazole compounds
US20040267017A1 (en) 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
CN112673009A (zh) 被取代的三唑并喹喔啉衍生物
KR20240035515A (ko) 삼중 고리 테트라하이드로 이소퀴놀린계 유도체의 염의 형태
Kinoyama et al. (+)-(2R, 5S)-4-[4-cyano-3-(trifluoromethyl) phenyl]-2, 5-dimethyl-N-[6-(trifluoromethyl) pyridin-3-yl] piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist
JP2013542202A (ja) Ｃｙｐ１７修飾因子として有用である置換ベンゾイミダゾールおよびイミダゾピリジン化合物
WO2025093755A1 (en) Novel parc inhibitors
WO2025133396A1 (en) Novel bicyclo heteroaryl parg inhibitors
US20040209924A1 (en) Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
CN116848103B (zh) Hpk1激酶抑制剂
US20260055106A1 (en) Parg inhibitory compound
WO2010141247A1 (en) Hexahydrocyclopentyl[∫]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
Srinivas et al. Design an Efficient Method for the Synthesis of 2-(1, 3-diphenyl-1H-pyrazol-4-yl)-1H-benzo [d] imidazole
BR112021012595B1 (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de uso para tratamento de câncer

Legal Events

Date Code Title Description
FZDE Dead